R Sasane

The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database

ABSTRACT Objective: The objective of this study was to examine the relationship of work loss associated with gastro-esophageal reflux disease (GERD) and peptic ulcer disease (PUD) in a large population of employed individuals in the United States (US) and quantify the economic impact of these diseases to the employer. Methods: A proprietary database that contained workplace absence, disability and workers’ compensation data in addition to prescription drug and medical claims was used to answer the objectives. Employees with a medical claim with an ICD-9 code for GERD or PUD were identified from 1 January 1997 to 31 December 2000. A cohort of controls was identified for the same time period using the method of frequency matching on age, gender, industry type, occupational status, and employment status. Work absence rates and health care costs were compared between the groups after adjusting for demographic, and employment differences using analysis of covariance models. Results: There were significantly lower ( p < 0.05) prescription, and outpatient costs in the controls compared to the disease groups, although the eta-square values were very low. The mean work absence attributed to sick days was 2.8 (± 2.3) for controls, 3.4 (± 2.5) for GERD, 3.2 (± 2.6) for PUD, and 3.2 (± 2.3) days for GERD + PUD. For work loss, a significantly higher ( p < 0.05) rate of adjusted all-cause absenteeism and sickness-related absenteeism were observed between the disease groups versus the controls. In particular, controls had an average of 1.2 to 1.6 days and 0.4 to 0.6 lower all-cause and sickness-related absenteeism compared to the disease groups. The incremental economic impact projected to a hypothetical employed population was estimated to be

Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population

3441 for GERD,

Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice

1374 for PUD, and

Patterns and effectiveness of lipid-lowering therapies in a managed care environment

4803 for GERD + PUD per employee per year compared to employees without these diseases. Conclusions: Direct medical cost and work absence in employees with GERD, PUD and GERD + PUD represent a significant burden to employees and employers.